autologous anti-CD19 CAR T cells GLPG5101

A preparation of autologous stem-like early memory T lymphocytes that have been genetically engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19, with potential immunomodulating and antineoplastic activities. Upon administration, autologous anti-CD19 CAR T cells GLPG5101 specifically recognize and kill tumor cells expressing CD19. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.